|
Orchid Pharma Limited (Orchpharma.NS) Évaluation DCF
IN | Healthcare | Drug Manufacturers - Specialty & Generic | NSE
|
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Orchid Pharma Limited (ORCHPHARMA.NS) Bundle
Simplifier Orchid Pharma Limited (OrchPharmans) Valation avec cette calculatrice DCF personnalisable! Doté de la véritable valeur des finances Orchid Pharma Limited (OrchPharmans), vous pouvez tester les scénarios et découvrir la juste valeur Orchid Pharma Limited (OrchPharmans) en minutes.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5,080.4 | 4,500.6 | 5,595.6 | 6,659.0 | 8,193.7 | 9,319.7 | 10,600.4 | 12,057.1 | 13,714.0 | 15,598.6 |
| Revenue Growth, % | 0 | -11.41 | 24.33 | 19 | 23.05 | 13.74 | 13.74 | 13.74 | 13.74 | 13.74 |
| EBITDA | 544.7 | 658.7 | 635.8 | 1,429.4 | 1,419.2 | 1,407.4 | 1,600.8 | 1,820.8 | 2,071.0 | 2,355.6 |
| EBITDA, % | 10.72 | 14.64 | 11.36 | 21.47 | 17.32 | 15.1 | 15.1 | 15.1 | 15.1 | 15.1 |
| Depreciation | 1,179.3 | 1,089.2 | 870.2 | 547.9 | 332.4 | 1,402.6 | 1,595.3 | 1,814.6 | 2,063.9 | 2,347.6 |
| Depreciation, % | 23.21 | 24.2 | 15.55 | 8.23 | 4.06 | 15.05 | 15.05 | 15.05 | 15.05 | 15.05 |
| EBIT | -634.6 | -430.4 | -234.4 | 881.5 | 1,086.8 | 4.8 | 5.4 | 6.2 | 7.0 | 8.0 |
| EBIT, % | -12.49 | -9.56 | -4.19 | 13.24 | 13.26 | 0.05136125 | 0.05136125 | 0.05136125 | 0.05136125 | 0.05136125 |
| Total Cash | 899.0 | 315.1 | 48.3 | 307.8 | 45.2 | 572.9 | 651.6 | 741.2 | 843.0 | 958.9 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 680.1 | 1,357.0 | 1,705.7 | 2,151.9 | 1,955.5 | 2,426.9 | 2,760.4 | 3,139.7 | 3,571.2 | 4,062.0 |
| Account Receivables, % | 13.39 | 30.15 | 30.48 | 32.32 | 23.87 | 26.04 | 26.04 | 26.04 | 26.04 | 26.04 |
| Inventories | 1,557.1 | 1,528.9 | 1,726.6 | 2,287.4 | 2,642.3 | 3,020.9 | 3,436.1 | 3,908.3 | 4,445.3 | 5,056.2 |
| Inventories, % | 30.65 | 33.97 | 30.86 | 34.35 | 32.25 | 32.41 | 32.41 | 32.41 | 32.41 | 32.41 |
| Accounts Payable | 1,015.9 | 1,099.5 | 1,676.8 | 1,743.7 | 2,295.8 | 2,397.0 | 2,726.4 | 3,101.0 | 3,527.2 | 4,011.9 |
| Accounts Payable, % | 20 | 24.43 | 29.97 | 26.19 | 28.02 | 25.72 | 25.72 | 25.72 | 25.72 | 25.72 |
| Capital Expenditure | -42.4 | -6.0 | -144.0 | -849.1 | -648.1 | -451.2 | -513.2 | -583.7 | -663.9 | -755.1 |
| Capital Expenditure, % | -0.83505 | -0.1342 | -2.57 | -12.75 | -7.91 | -4.84 | -4.84 | -4.84 | -4.84 | -4.84 |
| Tax Rate, % | -0.24069 | -0.24069 | -0.24069 | -0.24069 | -0.24069 | -0.24069 | -0.24069 | -0.24069 | -0.24069 | -0.24069 |
| EBITAT | -634.6 | -526.6 | -8.0 | 739.0 | 1,089.4 | 3.7 | 4.2 | 4.8 | 5.5 | 6.2 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -719.1 | -8.4 | 749.1 | -502.5 | 1,167.3 | 206.2 | 667.1 | 758.8 | 863.1 | 981.7 |
| WACC, % | 13.73 | 13.73 | 13.36 | 13.67 | 13.73 | 13.65 | 13.65 | 13.65 | 13.65 | 13.65 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 2,250.2 | |||||||||
| Long Term Growth Rate, % | 4.00 | |||||||||
| Free cash flow (T + 1) | 1,021 | |||||||||
| Terminal Value | 10,583 | |||||||||
| Present Terminal Value | 5,582 | |||||||||
| Enterprise Value | 7,832 | |||||||||
| Net Debt | 1,316 | |||||||||
| Equity Value | 6,517 | |||||||||
| Diluted Shares Outstanding, MM | 48 | |||||||||
| Equity Value Per Share | 134.74 |
What You Will Receive
- Comprehensive Financial Model: Leverage Orchid Pharma Limited’s (ORCHPHARMANS) actual data for accurate DCF valuation.
- Complete Forecast Flexibility: Modify revenue projections, profit margins, WACC, and other crucial parameters at your discretion.
- Real-Time Calculations: Enjoy automatic updates that reflect your changes immediately.
- Professional-Grade Template: An expertly designed Excel file ready for investor presentations.
- Customizable and Repeatable: Engineered for adaptability, enabling ongoing use for in-depth forecasting.
Key Features
- 🔍 Real-Life ORCHPHARMANS Financials: Pre-filled historical and projected data for Orchid Pharma Limited.
- ✏️ Fully Customizable Inputs: Adjust all essential parameters (yellow cells) such as WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas to determine Orchid’s intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Orchid’s valuation instantly upon making adjustments.
- Scenario Analysis: Evaluate and compare outcomes for various financial assumptions side-by-side.
How It Works
- Download: Obtain the comprehensive Excel file containing Orchid Pharma Limited’s financial data.
- Customize: Modify projections such as revenue growth, EBITDA %, and WACC to fit your analysis.
- Update Automatically: Watch as intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Develop various projections and instantly compare the results.
- Make Decisions: Leverage the valuation data to inform your investment approach with Orchid Pharma Limited (ORCHPHARMANS).
Why Choose Orchid Pharma Limited (ORCHPHARMANS)?
- Save Time: Skip the hassle of developing a financial model from the ground up – our tools are immediately available for use.
- Enhance Accuracy: Dependable financial data and calculations minimize valuation errors.
- Completely Customizable: Adjust the model to align with your unique assumptions and forecasts.
- User-Friendly: Intuitive charts and outputs simplify the analysis of results.
- Endorsed by Professionals: Crafted for experts who prioritize both precision and ease of use.
Who Should Use This Product?
- Investors: Accurately assess the fair value of Orchid Pharma Limited (ORCHPHARMANS) prior to making investment choices.
- CFOs: Utilize a professional-grade DCF model for comprehensive financial reporting and analysis.
- Consultants: Easily customize the template for client valuation reports.
- Entrepreneurs: Acquire insights into financial modeling techniques employed by leading companies.
- Educators: Employ it as a teaching resource to illustrate various valuation methodologies.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled historical data and forecasts for Orchid Pharma Limited (ORCHPHARMANS), including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for the Weighted Average Cost of Capital (WACC), featuring parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models presenting intrinsic value with comprehensive calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to facilitate thorough analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios tailored for Orchid Pharma Limited (ORCHPHARMANS).
- Dashboard and Charts: Visual summaries of valuation outputs and assumptions, making it easy to analyze results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.